NEW YORK (GenomeWeb News) – Agilent Technologies and BioNanomatrix will team to develop an integrated genetic analysis system with applications in genotoxicity and cytogenetics assay development, and potentially DNA sequencing, the companies said today.
Under the agreement, the companies plan to combine BioNanomatrix’s single-molecule imaging technology to develop chips and reagents with a measurement platform developed by Agilent.
Philadelphia-based BioNanomatrix is currently developing nanoscale single-molecule technology that will enable identification and analysis of an entire genome, the company said. The firm recently formed a joint venture with Complete Genomics to use an $8.8 million grant from the US National Institute of Standards and Technology to develop a platform aimed at sequencing a human genome in eight hours for under $100.
“BioNanomatrix’s unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine,” said Agilent GM of Life Sciences Solutions Nick Roelofs.
Financial terms of the agreement were not released.